JPRN-UMIN000003541已完成1 期
A phase 1 study of combination chemotherapy for hepatocellular carcinoma using Miripla® (SM11355) and IA-call® (DDP-H) - A combination chemotherapy of SM11355 and DDP-H for HCC (Phase 1)
iigata Hepatocellular Carcinoma Therapy Study Group0 个研究点目标入组 18 人开始时间: 2010年5月1日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 79years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Pleural effusion and/or ascites refractory to treatments. 2) Comorbidity: Active infectious diseases except for hepatitis. Active bleeding from GI tract. Active concomitant cancer with invasive nature. Severe mental disorder or hepatic encephalopathy. 3) A history of severe allergic reaction against iodine contrast medium and/or platinum agents. 4) A pregnant or lactating female or female of childbearing age unless using effective contraception. 5) Ongoing interferon therapy. 6) Difficulties of oral intake. 7) Other serious conditions judged to be inadequate by a responsible doctor.
研究者
相似试验
已完成
2 期
A phase 2 study of combination chemotherapy for hepatocellular carcinoma using Miripla (SM11355) and IA-call (DDP-H)Hepatocellular carcinomaJPRN-UMIN000004691iigata Hepatocellular Carcinoma Therapy Study Group200
已完成
2 期
Phase II study of combination chemotherapy and high-dose chemotherapy in treating young children with newly diagnosed medulloblastoma or supratentorial primitive neuroectodermal tumorsmedulloblastoma or supratentorial primitive neuroectodermal tumorsJPRN-UMIN000000546Japanese Pediatric Brain Tumor Consortium40
已完成
1 期
A phase I study of the combination chemotherapy of IRISOX (irinotecan/S-1/oxaliplatin) in gemcitabine-refractory pancreatic cancergemcitabine-refractory pancreatic cancerJPRN-UMIN000022964Kitasato University School of Medicine12
已完成
1 期
A phase 1 study of a combination chemotherapy, Sorafenib and intrahepatic arterial infusion of IA-call® (DDP-H), for advanced hepatocellular carcinoma.Hepatocellular carcinomaJPRN-UMIN000003831iigata Hepatocellular Carcinoma Therapy Study Group15
已完成
1 期
Phase I/II study of combination chemotherapy with Paclitaxel and TS-1 and Cisplatin for unresectable/ recurrent gastric cancerunresectable or recurrent gastric cancerJPRN-UMIN000004729School of Medicine, Keio University40